シクレソニドの世界市場： 規模、シェア、展望、機会分析（2022年～2028年）

世界のシクレソニドの市場規模は、アレルギー性鼻炎や喘息の高い有病率、主要地域における頻繁な製品の承認、主要企業による戦略的なM&Aの増加などによって促進されています。

当レポートでは、世界のシクレソニド市場を調査しており、市場の概要、市場規模や予測、動向、成長要因、抑制要因、適応症・剤形・地域別の分析、および競合情勢などを提供しています。

目次

第1章 調査目的・前提条件

• 調査目的
• 仮定
• 略語

第2章 市場概要

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場内訳：適応症別
  • 市場内訳：剤形別
  • 市場内訳：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 市場動向
• 新製品の承認と発売

第4章 世界のシクレソニド市場：適応症別（2017年～2028年）

• イントロダクション
• アレルギー性鼻炎
• 喘息

第5章 世界のシクレソニド市場：剤形別（2017年～2028年）

• イントロダクション
• エアロゾル
• 点鼻薬

第6章 世界のシクレソニド市場：地域別（2017年～2028年）

• イントロダクション
• 北米
• 米国
• カナダ
• 欧州
• 英国
• ドイツ
• イタリア
• フランス
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• 中国
• 日本
• インド
• ASEAN
• オーストラリア
• 韓国
• その他アジア太平洋
• ラテンアメリカ
• ブラジル
• メキシコ
• アルゼンチン
• その他ラテンアメリカ
• アフリカ
• 北アフリカ
• 中央アフリカ
• 南アフリカ
• 中東
• GCC諸国
• イスラエル
• その他中東

第7章 競合情勢

• ヒートマップ分析
• 企業プロファイル
  • AstraZeneca Plc
• 将来の戦略
  • Cipla Limited
• 将来の戦略
  • Sun Pharmaceutical Industries Ltd.
• 将来の戦略
  • Apotex Inc.
• 将来の戦略

第8章 セクション

Ciclesonide is an inhaled corticosteroids (ICS), recommended in asthma and chronic obstructive pulmonary disease (COPD) indication to get relief from difficulty in breathing, chest tightness, wheezing, and coughing. Inhaled drugs including inhaled corticosteroids, long acting B2 adrenoceptor agonists (LABA), and long acting muscarinic receptor antagonists (LAMA) are important treatment regime in the management of COPD. Inhaled corticosteroids are generally considered as safe and well tolerated in both adults and children. The improved safety and comparable efficacy profiles of ciclesonide demonstrated a potential treatment option which may lead to improved adherence and treatment outcome in asthma and COPD.

However, some of the studies raised concerns regarding increased risk of pneumonia related to regular use of ICS in adult patients with chronic obstructive pulmonary disease. A study findings published in the Respirology Journal: 2013, revealed an increased risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthma regularly taking ICS. This could potentially lead to restrict application of ciclesonide by patients during the forecast period.

Market Dynamics

Factors such as high prevalence of allergy rhinitis and asthma, and frequent product approval and launches in key regions are expected to drive the market growth over the forecast period. For instance, according to the Global Asthma Report published in 2021, it was estimated that globally asthma kills around 1,000 people every day and affects as many as 339 million people, worldwide. Furthermore, in 2012, Sunovion Pharmaceuticals Inc. received the U.S. Food and Drug Administration approval for its Zetonna (ciclesonide) nasal aerosol indicated for treatment of allergic rhinitis and launched it in the U.S. market.

Moreover, increasing strategic mergers and acquisitions by key players is also expected to support and drive the market growth. In 2012, Nycomed, a subsidiary of Takeda Pharmaceutical Company Ltd., launched Omnaris (ciclesonide) nasal spray, indicated for the treatment of adults and adolescents over the age of 12 with allergic rhinitis in the United Arab Emirates (UAE).

Key features of the study:

• This report provides in-depth analysis of ciclesonide market, its market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global ciclesonide market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study includes AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics.
• The global ciclesonide market report caters to various stakeholders in this industry including investors, researchers, ciclesonide manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the ciclesonide market.

Detailed Segmentation:

• Global Ciclesonide Market, By Indication:
• Allergy Rhinitis
• Asthma
• Global Ciclesonide Market, By Dosage Form:
• Aerosol
• Nasal Spray
• Global Ciclesonide Market, By Geography:
• North America
  • By Country:
• U.S.
• Canada
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Europe
  • By Country:
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Asia Pacific
  • By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Latin America
  • By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Middle East
  • By Country:
• GCC
• Israel
• Rest of Middle East
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Africa
  • By Country:
• North Africa
• Central Africa
• South Africa
  • By Indication:
• Allergy Rhinitis
• Asthma
  • By Dosage Form:
• Aerosol
• Nasal Spray
• Company Profiles
• AstraZeneca Plc*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments
  • Strategies
• Cipla Limited
• Sun Pharmaceutical Industries Ltd.
• Apotex Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Indication
  • Market Snippet, By Dosage Form
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• New Product Approvals & Launches

4. Global Ciclesonide Market, By Indication, 2017-2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Allergy Rhinitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
• Asthma
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)

5. Global Ciclesonide Market, By Dosage Form, 2017-2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Aerosol
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)
• Nasal Spray
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2028, (US$ Million)

6. Global Ciclesonide Market, By Region, 2017-2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, By Region, 2017 - 2028
• North America
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• U.S.
• Canada
• Europe
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• China
• Japan
• India
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Africa
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• North Africa
• Central Africa
• South Africa
• Middle East
  • Market Size and Forecast, By Indication, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Dosage Form, 2017-2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017-2028, (US$ Million)
• GCC Countries
• Israel
• Rest of Middle East

7. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • AstraZeneca Plc
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies
  • Cipla Limited
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies
  • Apotex Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Developments/Updates
• Future Strategies

8. Section

• References
• Research Methodology
• About Us and Sales Contact